These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26933896)

  • 1. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
    Alric L; Bonnet D
    Expert Opin Pharmacother; 2016; 17(5):735-42. PubMed ID: 26933896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
    Roth D; Nelson DR; Bruchfeld A; Liapakis A; Silva M; Monsour H; Martin P; Pol S; Londoño MC; Hassanein T; Zamor PJ; Zuckerman E; Wan S; Jackson B; Nguyen BY; Robertson M; Barr E; Wahl J; Greaves W
    Lancet; 2015 Oct; 386(10003):1537-45. PubMed ID: 26456905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
    Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
    Bruchfeld A; Roth D; Martin P; Nelson DR; Pol S; Londoño MC; Monsour H; Silva M; Hwang P; Arduino JM; Robertson M; Nguyen BY; Wahl J; Barr E; Greaves W
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):585-594. PubMed ID: 28576451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
    Buti M; Gordon SC; Zuckerman E; Lawitz E; Calleja JL; Hofer H; Gilbert C; Palcza J; Howe AY; DiNubile MJ; Robertson MN; Wahl J; Barr E; Forns X
    Clin Infect Dis; 2016 Jan; 62(1):32-6. PubMed ID: 26371152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
    Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
    Zeuzem S; Serfaty L; Vierling J; Cheng W; George J; Sperl J; Strasser S; Kumada H; Hwang P; Robertson M; Wahl J; Barr E; Talwani R; Platt H
    J Gastroenterol; 2018 May; 53(5):679-688. PubMed ID: 29344726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
    Zeuzem S; Ghalib R; Reddy KR; Pockros PJ; Ben Ari Z; Zhao Y; Brown DD; Wan S; DiNubile MJ; Nguyen BY; Robertson MN; Wahl J; Barr E; Butterton JR
    Ann Intern Med; 2015 Jul; 163(1):1-13. PubMed ID: 25909356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.
    Al-Salama ZT; Deeks ED
    Drugs; 2017 May; 77(8):911-921. PubMed ID: 28417245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
    Yeh WW; Fraser IP; Jumes P; Petry A; Lepeleire I; Robberechts M; Reitmann C; Van Dyck K; Huang X; Guo Z; Panebianco D; Nachbar RB; O'Mara E; Wagner JA; Butterton JR; Dutko FJ; Moiseev V; Kobalava Z; Hüser A; Visan S; Schwabe C; Gane E; Popa S; Ghicavii N; Uhle M; Wagner F
    Clin Ther; 2018 May; 40(5):704-718.e6. PubMed ID: 29703432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
    de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM
    Clin Infect Dis; 2018 Mar; 66(7):1013-1018. PubMed ID: 29077864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
    Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BY; Barr E; Platt HL; Robertson MN; Sulkowski M
    Lancet HIV; 2015 Aug; 2(8):e319-27. PubMed ID: 26423374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
    Sulejmani N; Jafri SM; Gordon SC
    Expert Opin Drug Metab Toxicol; 2016; 12(3):353-61. PubMed ID: 26849059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
    Forns X; Gordon SC; Zuckerman E; Lawitz E; Calleja JL; Hofer H; Gilbert C; Palcza J; Howe AY; DiNubile MJ; Robertson MN; Wahl J; Barr E; Buti M
    J Hepatol; 2015 Sep; 63(3):564-72. PubMed ID: 25895428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
    Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
    Karaoui LR; Mansour H; Chahine EB
    Am J Health Syst Pharm; 2017 Oct; 74(19):1533-1540. PubMed ID: 28947524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
    Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
    J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.